Table 1.
Inclusion and exclusion criteria of the patients recruited in the study.
Fig 1.
Kaplan–Meier survival plot showing the proportion of eyes without subretinal fluid after initial half-dose photodynamic therapy.
Recurrence continued to occur during the 5-year follow-up period.
Table 2.
Comparison of baseline clinical characteristics according to success of half-dose PDT.
Fig 2.
Long-term visual acuity changes following half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
Baseline best-corrected visual acuity (BCVA) significantly improved after 3, 6, 12, 24, and 36 months in the successful group and at 24 and 36 months in the unsuccessful group. All values are presented as mean ± standard error of the mean. *P < 0.05.
Fig 3.
Long-term subfoveal choroidal thickness changes following half-dose photodynamic therapy (PDT) in eyes with chronic central serous chorioretinopathy.
After PDT, baseline subfoveal choroidal thickness significantly decreased at each visit in the successful group and at 1, 3, 24, and 36 months in the unsuccessful group. All values are presented as mean ± standard error of the mean. *P < 0.05, **P < 0.01, ***P < 0.001.